any theories, page-9

My theory about NRT/NVGN and its share price has little to do with the company, its potential or even the sector its in. I look at it like this. Most people at some stage develop a lifestyle disease like diabetes, heart disease or say cancer. And their response is in many instances - OK what do I have to do to beat this. They wait until it happens. Few of us are really proactive to do something to avoid it occuring in the first place.

LIkewise, my view of Novogen and its share price is along similar lines. Regardless of its potential - just like the strong odds of developing a serious health problem - most investors will act when something big happens. And as we all probably know, that will be a successful human trial. Its the same line of thinking. Potential doesn't necessarily mean that someone is going to do something about it. And then over time, more will act upon FDA approval because earnings, profit and dividends then come into play.

q is right. I just wish I had the nerve to follow his advice.

Tumors eradicated in women with Ovarian cancer during a Phase 1 trial and I can't see the base benchmark for NRT being below $1. Any other opinions on this one?